Matthew Brendon Might, Ph.D.
Matthew Brendon Might, Ph.D.
Senior Lecturer on Biomedical Informatics, Part-time

As a computer scientist, Matt Might focuses on making software faster, safer and more secure. He has deep research expertise in automated, semantics-driven analysis of modern software systems and complex formal models. Additional research interests include domain-specific language design (especially for high-performance physical simulations) and novel techniques for efficient parsing of data in unrestricted (and potentially ambiguous) grammars. His work is funded by DARPA, NSF and the National Nuclear Security Administration. His interests in bioinformatics include Internet-driven case-finding for rare disease; systematizing delivery of care in genomic medicine; systems pharmacology; and in silico drug discovery. His true passion is accelerating the promise of genomic medicine for patients in need. In 2014, he was appointed one of six Presidential Scholars at the University of Utah. He received his Ph.D. in Computer Science from Georgia Tech in 2007. He regularly blogs at and tweets from @mattmight.

Induced pluripotent stem cells for neural drug discovery.
Authors: Farkhondeh A, Li R, Gorshkov K, Chen KG, Might M, Rodems S, Lo DC, Zheng W.
Drug Discov Today
View full abstract on Pubmed
Generation of an induced pluripotent stem cell line (TRNDi002-B) from a patient carrying compound heterozygous p.Q208X and p.G310G mutations in the NGLY1 gene.
Authors: Li R, Pradhan M, Xu M, Baskfield A, Farkhondeh A, Cheng YS, Beers J, Zou J, Liu C, Might M, Rodems S, Zheng W.
Stem Cell Res
View full abstract on Pubmed
anexVis: visual analytics framework for analysis of RNA expression.
Authors: Tran DT, Zhang T, Stutsman R, Might M, Desai UR, Kuberan B.
View full abstract on Pubmed
Plain-language medical vocabulary for precision diagnosis.
Authors: Vasilevsky NA, Foster ED, Engelstad ME, Carmody L, Might M, Chambers C, Dawkins HJS, Lewis J, Della Rocca MG, Snyder M, Boerkoel CF, Rath A, Terry SF, Kent A, Searle B, Baynam G, Jones E, Gavin P, Bamshad M, Chong J, Groza T, Adams D, Resnick AC, Heath AP, Mungall C, Holm IA, Rageth K, Brownstein CA, Shefchek K, McMurry JA, Robinson PN, Köhler S, Haendel MA.
Nat Genet
View full abstract on Pubmed
A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy.
Authors: Atkin TA, Maher CM, Gerlach AC, Gay BC, Antonio BM, Santos SC, Padilla KM, Rader J, Krafte DS, Fox MA, Stewart GR, Petrovski S, Devinsky O, Might M, Petrou S, Goldstein DB.
View full abstract on Pubmed
Transcriptome and functional analysis in a Drosophila model of NGLY1 deficiency provides insight into therapeutic approaches.
Authors: Owings KG, Lowry JB, Bi Y, Might M, Chow CY.
Hum Mol Genet
View full abstract on Pubmed
Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-ß-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease.
Authors: Bi Y, Might M, Vankayalapati H, Kuberan B.
Bioorg Med Chem Lett
View full abstract on Pubmed
What happens when N?=?1 and you want plus 1?
Authors: Might M, Might CC.
Prenat Diagn
View full abstract on Pubmed
Participant-driven matchmaking in the genomic era.
Authors: Lambertson KF, Damiani SA, Might M, Shelton R, Terry SF.
Hum Mutat
View full abstract on Pubmed
The shifting model in clinical diagnostics: how next-generation sequencing and families are altering the way rare diseases are discovered, studied, and treated.
Authors: Might M, Wilsey M.
Genet Med
View full abstract on Pubmed